Elevated proportion of eosinophils predicts immune-related adverse events and improved survival in patients with gastric cancer treated with nivolumab
{{output}}
Background: Immune checkpoint inhibitors (ICIs) have improved treatment outcomes for gastric cancer. However, immune-related adverse events (irAEs) pose a major challenge. This study aimed to identify predictive factors for irAE ... ...
